Larry M Karnitz - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Larry M Karnitz

Showing results (51-60 of 53) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 53 results.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.

Cell Reports. Medicine|January 14, 2022

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancerDongqing Huang, Shrabanti Chowdhury, Hong Wang, et al.

NAR Cancer|July 28, 2021

Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.

Pageof 6

Search research articles

Showing results (51-60 of 53) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 53 results.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.

Cell Reports. Medicine|January 14, 2022

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancerDongqing Huang, Shrabanti Chowdhury, Hong Wang, et al.

NAR Cancer|July 28, 2021

Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.

Pageof 6